Related Experiment Video

Updated: Dec 25, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

miR-143 inhibits renal cell carcinoma cells metastatic potential by suppressing ABL2

Bin Xu1, Can Wang1, Ya-Li Wang1

  • 1Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.

The Kaohsiung Journal of Medical Sciences
|March 21, 2020
PubMed

Insights

MicroRNA (miRNA) hsa-miR-143 acts as a tumor suppressor in renal cell carcinoma (RCC). Its downregulation correlates with poor prognosis, inhibiting cancer cell adhesion, migration, and epithelial-mesenchymal transition (EMT).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNA (miRNA) expression is altered in renal cell carcinoma (RCC), but their functional roles in cancer initiation and progression are not fully understood.
  • Investigating miRNA profiles is crucial for understanding metastatic RCC pathogenesis.

Purpose of the Study:

  • To identify aberrant miRNA expression profiles in metastatic RCC.
  • To elucidate the functional and mechanistic roles of specific miRNAs in RCC progression.
  • To explore potential therapeutic targets for RCC.

Main Methods:

  • Analysis of miRNA expression data from Gene Expression Omnibus (GSE37989) and The Cancer Genome Atlas (TCGA) datasets.
  • Assessment of cell adhesion, migration, and epithelial-mesenchymal transition (EMT) in RCC cell lines.
  • Target validation of miRNA-gene interactions.

Main Results:

  • Downregulation of hsa-miR-143 was observed in metastatic RCC and correlated with adverse prognosis.
  • Overexpression of miR-143 significantly inhibited cell adhesion, migration, and EMT.
  • ABL proto-oncogene 2 (ABL2) was identified as a direct target of miR-143, and its high expression indicated poor survival in RCC patients.

Conclusions:

  • hsa-miR-143 functions as a tumor suppressor in RCC by targeting ABL2.
  • miR-143 plays a critical role in regulating cell adhesion, migration, and EMT in RCC.
  • These findings provide insights into miRNA functions in metastatic RCC and suggest miR-143 as a potential therapeutic target.
Keywords:
ABL2metastasismiRNArenal cell carcinoma

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K